HEP-1 (Gepon): Human Ezrin Peptide, NF-κB/IL-6 Axis Suppression, and Adaptive Immunity Amplification

Molecular Identity and Structural Architecture Ezrin Protein Origin and the Hep-Receptor Human ezrin is a member of the ERM (Ezrin-Radixin-Moesin) family of proteins that function as linkers between the actin cytoskeleton and the plasma membrane. Ezrin exists in two distinct conformational states: a closed/inactive cytoplasmic form and an open/active submembrane form. The transition between these states is regulated by phosphorylation and is critical for the organisation of multi-protein cell-signalling complexes at the cell surface, including adhesion molecules, receptors, adaptor proteins, kinases, and cytoskeletal components. The 'Hep-receptor' refers to a surface-exposed receptor transition conformation of ezrin present on the exterior surface of cell membranes. HEP-1 was designed to mimic and bind to this receptor conformation. Critically, the molecular origin of HEP-1 traces to the discovery by Dr Holms in the early 1990s that the amino acid sequence at the C-terminus of HIV gp120 mimics part of the Alpha domain of human ezrin. This molecular mimicry is mutation-stable, indicating functional conservation, and provided the structural template for the development of HEP-1. Sequence Characteristics and Physicochemical Properties The primary sequence of HEP-1 is Thr-Glu-Lys-Lys-Arg-Arg-Glu-Thr-Val-Glu-Arg-Glu-Lys-Glu (TEKKRRETVEREKE), corresponding to amino acids 324–337 of the human ezrin Alpha domain. The molecular formula is C₄H₁₃₂N₂₆O₂₇, with a molecular weight of approximately 1.7 kDa. The peptide adopts a 4-turn alpha-helical conformation and is highly charged due to the abundance of basic residues (Lys, Arg) and acidic residues (Glu), rendering it highly soluble in aqueous solution. HEP-1 is stable at room temperature in solid form for at least two years and degrades at approximately 1% per month in aqueous solution, making it suitable for pharmaceutical formulation and storage. The active substance is inexpensive to manufacture, and the peptide is active on mucosal membrane surfaces, enabling nasal, sublingual, and topical administration routes in addition to injection. Mechanistic Rationale: Dual Immunomodulatory Action Ezrin Conformational Activation and Membrane Signalling Upon binding to the Hep-receptor conformation of ezrin on the exterior of cell membranes, HEP-1 induces allosteric changes in the submembrane multi-protein complex, stimulating the transition from the closed/inactive to the open/active conformation of ezrin. This conformational shift results in enhanced receptor clustering and the organisation of membrane-associated cell-signalling complexes, triggering intracellular signalling cascades. The primary downstream pathway activated is the PKA (protein kinase A) CREB (cAMP response element-binding protein) signalling axis, which plays a central role in both the anti-inflammatory and immune-amplifying effects of HEP-1. NF-κB/IL-6 Axis Suppression: Anti-inflammatory Mechanism One of the most significant pharmacological properties of HEP-1 is its capacity to suppress NF-κB-mediated chronic expression of pro-inflammatory cytokines. NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a master transcriptional regulator of inflammation, controlling the expression of IL-1β, IL-6, IL-8, and TNFα. Dysregulated NF-κB activation underlies a broad spectrum of inflammatory and infectious diseases, from viral hepatitis and ulcerative colitis to cytokine storm in COVID-19. HEP-1 suppresses NF-κB activation through the induction of PKA CREB signalling, which counteracts the RAGE (Receptor for Advanced Glycation End-products) / TLR4 (Toll-Like Receptor 4) pro-inflammatory feedback loop. In the context of SARS-CoV-2 infection, spike protein binding to mRAGE and TLR4 triggers hyperexpression of PKC, p38, NF-κB, and IL-6, establishing a self-sustaining inflammatory loop. HEP-1 interrupts this loop by inducing PKA CREB signalling, thereby reducing IL-6, IL-8, and TNFα expression and attenuating the cytokine storm. "Ezrin peptides amplify adaptive immunity through the RANTES/CCL5 pathways that lead to cures of drug resistant infections due to bacteria, viruses, fungi and protozoans. Ezrin peptides simultaneously suppress chronic pro-inflammatory cytokine and chemokine signalling, leading to cures for chronic inflammatory disease." — Holms RD. Microbiol Immunol Pathol. 2024 RANTES/CCL5 Pathway: Adaptive Immunity Amplification In parallel with its anti-inflammatory activity, HEP-1 amplifies adaptive immunity through the RANTES/CCL5 (Regulated on Activation, Normal T Cell Expressed and Secreted / C-C Motif Chemokine Ligand 5) chemokine pathway. RANTES/CCL5 is a critical chemokine that recruits T cells, NK cells, dendritic cells, and monocytes to sites of infection and inflammation, and plays a central role in the coordination of adaptive immune responses against viral pathogens. Evidence for this mechanism emerged from blood results in a Long COVID vaccine injury patient treated with

For research use only. Not for human consumption.